We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Name | Symbol | Market | Type |
|---|---|---|---|
| GSK plc | NYSE:GSK | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.35 | -0.87% | 39.66 | 40.005 | 39.63 | 39.97 | 1,113,427 | 16:30:30 |
From Jul 2021 to Jul 2024
By Joe Hoppe
GlaxoSmithKline PLC's monoclonal antibody treatment for the coronavirus, sotrovimab, has been limited in use by the U.S. Food and Drug Administration, the federal agency said late Wednesday.
The pharmaceutical giant's product shouldn't be used to treat patients with mild-to-moderate infections in places where the disease is likely to have been caused by a variant that isn't susceptible to the drug, the FDA said.
GlaxoSmithKline's partner Vir Biotechnology Inc. has previously said sotrovimab retains its neutralizing of the activity of the emerging BA.2 form of the Omicron variant of the coronavirus.
The FDA said it will monitor conditions to determine whether the drug should be used in certain geographic regions.
Shares at 1011 GMT were down 4.2 pence, or 0.3%, at 1,545.8 pence.
Write to Joe Hoppe at joseph.hoppe@wsj.com
(END) Dow Jones Newswires
February 24, 2022 05:29 ET (10:29 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year GSK Chart |
1 Month GSK Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
